MedTrace Logo

Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage

NCT01252160 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2018-04-19

No results posted yet for this study

Summary

In this study all patients will be treated with the same medicine, the QUTENZA patch. Subjects will receive up to 6 QUTENZA patch applications over 12 months.

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

QUTENZA

Cutaneous patch

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Europe Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-28
Primary Completion
2013-09-26
Completion
2013-09-26

Countries

  • Austria
  • Belgium
  • Czechia
  • Finland
  • France
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Netherlands
  • Poland
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01252160 on ClinicalTrials.gov